Francesca M Gay

43PUBLICATIONS
244CO-AUTHORS
Gene and molecular therapyMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (43)

|Aug 27, 2026
Optimizing the Real-World Use of BCMA-Targeted T-Cell-Engaging Therapies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: An Italian Modified Delphi Consensus.

|May 13, 2026
MDM2 Drives Proteasome Inhibitor Resistance and Represents a TP53-Independent Therapeutic Vulnerability in Multiple Myeloma.

|Apr 06, 2026
Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial.

Francesca Gay, Wilfried Roeloffzen, Meletios A Dimopoulos

|Mar 11, 2026
Genetic Evidence against Clonotypic B Lymphocytes as a Reservoir for Plasma-cell Cancers.

Carmen González, Juan-Jose Garces, Hector Gracia

|Dec 10, 2025
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study.

Rakesh Popat, Meral Beksac, Meletios A Dimopoulos

|Aug 14, 2025
Correction: Mancuso et al. Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma. Cancers 2025, 17, 1168.

Katia Mancuso, Simona Barbato, Francesco Di Raimondo

Pageof 8

Frequent Collaborators

10 joint publications

Pellegrino Musto

10 joint publications

Pieter Sonneveld

9 joint publications

Maria-Victoria Mateos

7 joint publications

Jesús San-Miguel Izquierdo